Navigation Links
Lotus Pharmaceuticals, Inc. Again Awarded GSP Certification
Date:6/29/2009

BEIJING, June 29 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS) ("Lotus" or the "Company") a growing developer and producer of prescriptions drugs and licensed national seller of pharmaceutical products in the People's Republic of China, today reported it received a Good Supply Practices ("GSP") certificate from the Chinese State Food & Drug Administration ("SFDA") for the second time since 2003.

Liang Fang Pharmaceutical, Ltd., operated by Lotus, passed the SFDA's GSP field inspection and documentation requirement for, among other items, its sales management system, storage and transportation system, qualifications of medical and management personnel, drugs quality control system, drugs labeling and packaging. To maintain drugs safety, post sale services and systematic quality control of drugs out of production into the circulation, the SFDA requires licensed drug distributors to follow the international principles and guidelines of GSP. The SFDA focuses on quality assurance systems, tracking systems, storage and transportation systems and handling procedures and inspects drugs distributors every five years.

"We are delighted to be awarded with GSP certification because it represents the highest honor that a licensed pharmaceutical sales enterprise is eligible to receive in China for its compliance with the government's high quality standards and efficient management system control," commented Dr. Zhongyi Liu, Chairman and CEO of Lotus. "We are committed to providing safe drugs and in addition to our current state-of-art warehouse, we are planning on the construction of a high standard modern storage facility of 10000 sqm in Inner Mongolia in order to meet the increasing demand for our drugs."

About Lotus Pharmaceuticals, Inc. ( http://www.lotuspharma.com )

Lotus Pharmaceuticals, Inc. is a growing developer and producer of prescription drugs and a licensed national seller of pharmaceutical items in the People's Republic of China. Lotus operates Liang Fang Pharmaceutical, Ltd. and En Ze Jia Shi Pharmaceutical, Ltd. Lotus' current drug development pipeline is focused on the treatment of cerebro-cardiovascular disease, asthma, and diabetes. More than 8,000 products are sold by Liang Fang directly and indirectly through its national sales channels to hospitals, clinics and drugs stores in 30 provinces.

Safe Harbor Statement

This press release contains "forward-looking statements" within the meaning of the "safe-harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intent," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "should," "could," "would," "may," or words or expressions of similar meaning. Such statements are not guarantees of future performance and could cause the actual results of the Company to differ materially from the results expressed or implied by such statements, including, but not limited to, changes from anticipated levels of sales, future national or regional economic and competitive and regulatory conditions, changes in relationships with customers, access to capital, increased costs, difficulties in developing and marketing new products, marketing existing products, customer acceptance of existing and new products, the time to get new drugs approved by the SFDA and other factors. Additional information regarding risks can be found in the Company's Annual Report on Form 10K and its older filings with the SEC. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company has no obligation to update the forward-looking information contained in this press release.

    Lotus Pharmaceuticals, Inc.
     Yan Zeng, CFO
     Email: zy@lotuspharma.com
     Web:  http://www.lotuspharma.com

'/>"/>
SOURCE Lotus Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Lotus Pharmaceuticals, Inc. to Exhibit at the 2009 International Conference for Bioeconomy
2. Lotus Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results
3. Lotus Pharmaceuticals, Inc. Reports Strong 2008 Financial Results
4. iEnterprises Launches iComply, Lotus Notes Email Archiving and Compliance Software
5. Lotus Pharmaceuticals, Inc. Purchases Intellectual Property Rights to an Established Prescription Drug
6. Lotus Pharmaceuticals, Inc. Purchases Land Use Rights to Grow its Business and Reduce Costs
7. Lotus Pharmaceuticals to Present at Rodman & Renshaw Conference
8. Lotus Pharmaceuticals Announces Conference Call to Discuss Second Quarter 2008 Results
9. Lotus Pharmaceuticals, Inc. Reaffirms its Confidence in Meeting its Make Good Target for Fiscal Year 2008
10. Lotus Pharmaceuticals, Inc. Announces Conference Call to Discuss First Quarter 2008 Results
11. Lotus Pharmaceuticals, Inc. Announces Resignation of Director Mel Rothberg
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June ... , brings up a new, often overlooked aspect of head lice: the parasite’s ability to ... is not a common occurrence, but a necessary one in the event that lice have ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, ... Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments in ... the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in ...
(Date:6/24/2016)... ... ... crisis. Her son James, eight, was out of control. Prone to extreme mood shifts and ... him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife on ... say he was going to kill them. If we were driving on the freeway, ...
(Date:6/24/2016)... ... 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ... raise to $12 an hour by 2020 and then adjusting it yearly to increase at ... the minimum wage, assure the wage floor does not erode again, and make future increases ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, LLC (SCP) ... obtaining investment capital for emerging technology companies. SCP has delivered investment events ... in more than a million dollars of capital investment for five companies. ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... June 27, 2016 Jazz Pharmaceuticals plc (Nasdaq: ... under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as ... Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: CPXX ) ... Daylight Time). As previously announced on May ... definitive merger agreement under which Jazz Pharmaceuticals has commenced ...
(Date:6/26/2016)... 2016 Story Highlights: ... within the health care industry is causing providers to ... , Deloitte offers a suite of solutions for health ... efficient cost optimization: labor resource analysis, revenue cycle optimization ... better outcomes and better economics ...
(Date:6/24/2016)... 2016  Collagen Matrix, Inc., ("Collagen Matrix") the ... of collagen and mineral based medical devices for ... Bill Messer has joined the company as ... the growing portfolio of oral surgery, neurosurgery, orthopaedic ... joins the Collagen Matrix executive team as an ...
Breaking Medicine Technology: